Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in Newly Diagnosed Primary Immune Thrombocytopenia
NCT03692754Phase 3Unknown
- Sponsor
- Shandong University
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of atorvastatin in immune thrombocytopenia (ITP) (3 arms), sponsored by Shandong University. Primary endpoint: Evaluation of platelet response up to 1 year. Status: unknown.
02
Drugs
atorvastatin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03692754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692754.